RAPT Therapeutics/ US75382E1091 /
9/10/2024 9:59:55 PM | Chg. -0.03 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
2.00USD | -1.24% | 4,781 Turnover: 9,485.26 |
-Bid Size: - | -Ask Size: - | 2.09 | 1.92 |
GlobeNewswire
5/9
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeut...
GlobeNewswire
4/9
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with...
GlobeNewswire
3/12
RAPT ALERT: Bragar Eagel & Squire, P.C. is Investigating RAPT Therapeutics, Inc. on Behalf of RAPT S...
GlobeNewswire
3/7
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...
GlobeNewswire
3/5
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Associatio...
GlobeNewswire
2/28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...
GlobeNewswire
2/21
RAPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claim...
GlobeNewswire
2/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutic...
GlobeNewswire
2/20
Investigation of RAPT Therapeutics, Inc. (RAPT) Announced by Holzer & Holzer, LLC
GlobeNewswire
2/13
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vic...
GlobeNewswire
1/31
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Confere...
GlobeNewswire
11/27/2023
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Tre...
GlobeNewswire
11/3/2023
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free S...
GlobeNewswire
11/1/2023
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
GlobeNewswire
10/18/2023
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SIT...
GlobeNewswire
8/30/2023
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
GlobeNewswire
3/28/2022
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Mod...
GlobeNewswire
3/10/2022
RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results
GlobeNewswire
2/15/2022
Portage Biotech Announces New Appointments to its Management Team and Board of Directors